Posted by Michael Wonder on 22 Dec 2021
PHARMAC publishes experts’ advice and seeks views on patient access criteria for COVID-19 treatments
22 December 2021 - PHARMAC is releasing the October meeting records of their COVID-19 clinical expert advisory group and seeking feedback on the patient access criteria for two funded COVID-19 treatments – baricitinib and casirivimab and imdevimab (branded as Ronapreve).
Baricitinib is being proposed for use in hospital for those with moderate to severe symptoms of COVID-19, as an alternative treatment option to tocilizumab if this is not available. Baricitinib is not currently Medsafe approved for use in the treatment of COVID-19 and clinicians will need to comply with section 25 of the Medicines Act 1981.
Ronapreve is being proposed for use in hospital for patients with COVID-19 who have mild to moderate symptoms and are at high risk of progressing to severe disease.
